Articles scientifiques

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

Auteurs : Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M
Année : 2016
Journal : ESMO Open
Volume : 1
Pages : e000107

Managing Hodgkin lymphoma without chemotherapy: a novel, yet 'welcomed', challenge.

Auteurs : Kourie HR, Tabchi S, Kattan J
Année : 2016
Journal : Future Oncol
Volume : 12(12)
Pages : 1435-7

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.

Auteurs : Tolaney SM, Nechushtan H, Ron IG, Schöffski P, Awada A, Yasenchak CA, Laird AD, OKeeffe B, Shapiro GI, Winer EP
Année : 2016
Journal : Breast Cancer Res Treat
Volume : 160
Pages : 305-312

Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice.

Auteurs : Lalami Y, Awada A
Année : 2016
Journal : Cancer Treat Rev
Volume : 43
Pages : 113-23

Adjuvant endocrine therapy in preand perimenopausal women with breast cancer: practice guidelines

Auteurs : Duhoux F, Neven P, Awada A, Berlière M, Wildiers H, Denys H
Année : 2016
Journal : Belgian J Medical Oncology
Volume : 10(3)
Pages : 92-96

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer.

Auteurs : Twelves C, Awada A, Cortes J, Yelle L, Velikova G, Olivo MS, Song J, Dutcus CE, Kaufman PA
Année : 2016
Journal : Breast Cancer (Auckl)
Volume : 10
Pages : 77-84

Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients.

Auteurs : Maiter D, Bex M, Vroonen L, TSjoen G, Gil T, Banh C, Chadarevian R
Année : 2016
Journal : Ann Endocrinol (Paris)
Volume : 77(5)
Pages : 578-85

Threat posed by unproven drugs in medical oncology.

Auteurs : Pondé N, Ades F, de Azambuja E
Année : 2016
Journal : ESMO Open
Volume : 1
Pages : e000064

Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue

Auteurs : Kotecki N, Awada A, Bonneterre J, Hebbar M, Adenis A, Cortot AB, Cousin C, Clisant S, Duhamel A, Penel N
Année : 2016
Journal : Pharmaceutical Medicine
Volume : 30(3)
Pages : 143-7

Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise?

Auteurs : Morgan G, Aftimos P, Awada A
Année : 2016
Journal : Curr Opin Oncol
Volume : 28(5)
Pages : 441-6

Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.

Auteurs : Woff E, Hendlisz A, Garcia C, Deleporte A, Delaunoit T, Maréchal R, Holbrechts S, Van den Eynde M, Demolin G, Vierasu I, Lhommel R, Gauthier N, Guiot T, Ameye L, Flamen P
Année : 2016
Journal : Eur J Nucl Med Mol Imaging
Volume : 43(10)
Pages : 1792-801

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

Auteurs : Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell orto P, Rothé F, Laïos I, Ditzel HJ, Regan MM, Piccart-Gebhart M, Michiels S, Sotiriou C
Année : 2016
Journal : JAMA Oncol
Volume : 2(2)
Pages : 217-24

Twenty years of anti-HER2 therapy-associated cardiotoxicity.

Auteurs : Pondé NF, Lambertini M, de Azambuja E
Année : 2016
Journal : ESMO Open
Volume : 1
Pages : e000073

A Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early FDG PET-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.

Auteurs : Lalami Y, Garcia C, Flamen P, Ameye L, Paesmans M, Awada A
Année : 2016
Journal : Head Neck
Volume : 38(3)
Pages : 347-54

Eribulin in the soft tissue sarcoma therapeutic landscape: little is good, then more is better

Auteurs : Awada A, Penel N, Kotecki N
Année : 2016
Journal : TCR
Volume : 5(6)
Pages : s1160-62

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.

Auteurs : Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, Chmielik E, Christgen M, Colpaert C, Demaria S, Van den Eynden G, Floris G, Fox SB, Gao D, Ingold Heppner B, Kim SR, Kos Z, Kreipe HH, Lakhani SR, Penault-Llorca F, Pruneri G, Radosevic-Robin N, Rimm DL, Schnitt SJ, Sinn BV, Sinn P, Sirtaine N, OToole SA, Viale G, Van de Vijver K, de Wind R, Von Minckwitz G, Klauschen F, Untch M, Fasching PA, Reimer T, Willard-Gallo K, Michiels S, Loi S, Salgado R
Année : 2016
Journal : Mod Pathol
Volume : 29(10)
Pages : 1155-64

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.

Auteurs : Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, Goswami C, Deo S, Bose R, Wong A, Xu F, Yao B, Bryce R, Carey LA
Année : 2016
Journal : JAMA Oncol
Volume : 2(12)
Pages : 1557-64

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Auteurs : Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y
Année : 2016
Journal : ESMO Open
Volume : 1
Pages : e000097

An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.

Auteurs : Awada A, Campone M, Varga A, Aftimos P, Frenel JS, Bahleda R, Gombos A, Bourbouloux E, Soria JC
Année : 2016
Journal : Anticancer Drugs
Volume : 27(4)
Pages : 342-8

Metastatic breast cancer: The Odyssey of personalization.

Auteurs : Sonnenblick A, Pondé N, Piccart-Gebhart M
Année : 2016
Journal : Mol oncol
Volume : 10(8)
Pages : 1147-59